Challenges in vascular tissue engineering for diabetic patients
Source abstract
Abstract
Hyperglycemia and dyslipidemia coexist in diabetes and result in inflammation, degeneration, and impaired tissue remodeling, processes which are not conducive to the desired integration of tissue engineered products into the surrounding tissues. There are several challenges for vascular tissue engineering such as non-thrombogenicity, adequate burst pressure and compliance, suturability, appropriate remodeling responses, and vasoactivity, but, under diabetic conditions, an additional challenge needs to be considered: the aggressive oxidative environment generated by the high glucose and lipid concentrations that lead to the formation of advanced glycation end products (AGEs) in the vascular wall. Extracellular matrix-based scaffolds have adequate physical properties and are biocompatible, however, these scaffolds are altered in diabetes by the formation AGEs and impaired collagen degradation, consequently increasing vascular wall stiffness. In addition, vascular cells detect and respond to altered stimuli from the matrix by pathological remodeling of the vascular wall. Due to the immunomodulatory effects of mesenchymal stem cells (MSCs), they are frequently used in tissue engineering in order to protect the scaffolds from inflammation. MSCs together with antioxidant treatments of the scaffolds are expected to protect the vascular grafts from diabetes-induced alterations. In conclusion, as one of the most daunting environments that could damage the ECM and its interaction with cells is progressively built in diabetes, we recommend that cells and scaffolds used in vascular tissue engineering for diabetic patients are tested in diabetic animal models, in order to obtain valuable results regarding their resistance to diabetic adversities. Statement of significance Almost 25 million Americans have diabetes, characterized by high levels of blood sugar that binds to tissues and disturbs the function of cardiovascular structures. Therefore, patients with diabetes have a high risk of cardiovascular diseases. Surgery is required to replace diseased arteries with implants, but these fail after 5-10 years because they are made of non-living materials, not resistant to diabetes. New tissue engineering materials are developed, based on the patients' own stem cells, isolated from fat, and added to extracellular matrix-based scaffolds. Our main concern is that diabetes could damage the tissue-like implants. Thus we review studies related to the effect of diabetes on tissue components and recommend antioxidant treatments to increase the resistance of implants to diabetes.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
2. Vascular complications of diabetes10.1161/CIRCRESAHA.115.306884 ↗
3. Obesity, diabetes, and cardiovascular diseases: a compendium10.1161/CIRCRESAHA.116.308999 ↗
4. Diabetes, hypertension, and cardiovascular disease: an update10.1161/01.HYP.37.4.1053 ↗
5. Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators10.1016/j.tem.2012.10.002 ↗
6. Treatment of peripheral arterial disease in diabetes: a consensus of the Italian Societies of Diabetes (SID, AMD), Radiology (SIRM) and Vascular Endovascular Surgery (SICVE)10.1016/j.numecd.2013.12.007 ↗
7. Diabetes, peripheral arterial disease in people with diabetes10.2337/diacare.26.12.3333 ↗
8. Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation10.1016/j.jvs.2007.02.029 ↗
9. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy10.1161/01.CIR.0000129767.45513.71 ↗
10. The impact of diabetic status on coronary artery bypass graft patency: insights from the radial artery patency study
11. Tissue engineering of blood vessels: functional requirements, progress, and future challenges10.1007/s13239-011-0049-3 ↗
12. Biomaterials for vascular tissue engineering10.2217/rme.09.77 ↗
13. The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt10.1016/j.biomaterials.2006.09.048 ↗
14. Vascular endothelium summary statement VI: research directions for the 21st century10.1016/j.vph.2006.10.016 ↗
15. The tissue-engineered vascular graft-past, present, and future
16. Synthesis, characterization, and cytocompatibility of elastomeric, biodegradable poly(ester-urethane)ureas based on poly(caprolactone) and putrescine10.1002/jbm.10204 ↗
17. Mechanical stimulation induces morphological and phenotypic changes in bone marrow-derived progenitor cells within a three-dimensional fibrin matrix10.1002/jbm.a.31041 ↗
18. Human tissue-engineered blood vessels for adult arterial revascularization10.1038/nm1364 ↗
19. Development of a tissue-engineered vascular graft combining a biodegradable scaffold, muscle-derived stem cells and a rotational vacuum seeding technique10.1016/j.biomaterials.2007.10.044 ↗
20. Adult stem cell-based tissue engineered blood vessels: a review10.1016/j.biomaterials.2012.01.014 ↗
21. Cardiovascular tissue engineering10.1016/S1054-8807(02)00130-8 ↗
22. The extracellular matrix as a biologic scaffold material10.1016/j.biomaterials.2007.04.043 ↗
23. Extracellular matrix as a biological scaffold material: structure and function10.1016/j.actbio.2008.09.013 ↗
24. Polyphenol-stabilized tubular elastin scaffolds for tissue engineered vascular grafts10.1089/ten.tea.2008.0394 ↗
25. Decellularized matrices for cardiovascular tissue engineering
26. A critical role for elastin signaling in vascular morphogenesis and disease10.1242/dev.00223 ↗
27. Regulation of hyaluronan synthesis in vascular diseases and diabetes
28. Hyaluronidase 1 deficiency preserves endothelial function and glycocalyx integrity in early streptozotocin-induced diabetes10.2337/db15-1662 ↗
29. Hyaluronan oligosaccharides promote diabetic wound healing by increasing angiogenesis10.1016/j.pharep.2016.07.001 ↗
30. Stem cell-containing hyaluronic acid-based spongy hydrogels for integrated diabetic wound healing10.1016/j.jid.2017.02.976 ↗
31. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine10.1016/j.biomaterials.2012.02.034 ↗
32. Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix10.1093/cvr/cvw206 ↗
33. Amino acid sequence and antigenicity of the amino-terminus of the 168 kDa adherence protein of Mycoplasma pneumoniae
34. Elastin as a matrikine10.1016/j.critrevonc.2003.09.007 ↗
35. 67-kD elastin-binding protein is a protective “companion” of extracellular insoluble elastin and intracellular tropoelastin10.1083/jcb.126.2.563 ↗
36. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells10.1016/j.bbrc.2005.06.119 ↗
37. Xenogeneic extracellular matrix as a scaffold for tissue reconstruction10.1016/j.trim.2003.12.016 ↗
38. Regenerative potential of decellularized porcine nucleus pulposus hydrogel scaffolds: stem cell differentiation, matrix remodeling, and biocompatibility studies10.1089/ten.tea.2012.0088 ↗
39. Mitigation of diabetes-related complications in implanted collagen and elastin scaffolds using matrix-binding polyphenol10.1016/j.biomaterials.2012.09.081 ↗
40. Structural and biomechanical characterizations of porcine myocardial extracellular matrix10.1007/s10856-012-4660-0 ↗
41. Assembly and testing of stem cell-seeded layered collagen constructs for heart valve tissue engineering10.1089/ten.tea.2010.0138 ↗
42. Novel tissue-derived biomimetic scaffold for regenerating the human nucleus pulposus10.1002/jbm.a.33001 ↗
43. Macrophage differentiation and polarization on a decellularized pericardial biomaterial10.1016/j.biomaterials.2010.09.004 ↗
44. Fabrication of cardiac patch with decellularized porcine myocardial scaffold and bone marrow mononuclear cells10.1002/jbm.a.32781 ↗
45. Design and testing of a pulsatile conditioning system for dynamic endothelialization of polyphenol-stabilized tissue engineered heart valves10.1007/s13239-010-0014-6 ↗
46. Stabilized collagen scaffolds for heart valve tissue engineering10.1089/ten.tea.2008.0263 ↗
47. Novel porous aortic elastin and collagen scaffolds for tissue engineering10.1016/j.biomaterials.2003.12.019 ↗
48. Engineered whole organs and complex tissues10.1016/S0140-6736(12)60073-7 ↗
49. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products10.1172/JCI119229 ↗
50. Mechanisms for the formation of glycoxidation products in end-stage renal disease10.1046/j.1523-1755.2000.00117.x ↗
51. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept10.1016/S0008-6363(97)00233-2 ↗
52. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications10.2337/db11-1120 ↗
53. Role of nonenzymatic glycosylation in atherogenesis10.1002/jcb.240300203 ↗
54. Molecular and cellular mechanisms of cardiovascular disorders in diabetes10.1161/CIRCRESAHA.116.306923 ↗
55. Human acellular dermal wound matrix for complex diabetic wounds
56. Complication rates with human acellular dermal matrices: retrospective review of 211 consecutive breast reconstructions10.1097/GOX.0000000000001118 ↗
57. A meta-analysis of outcomes using acellular dermal matrix in breast and abdominal wall reconstructions: event rates and risk factors predictive of complications10.1097/SAP.0b013e31822afae5 ↗
58. Differences in the performance of PCL-based vascular grafts as abdominal aorta substitutes in healthy and diabetic rats10.1039/C6BM00178E ↗
59. V. Investigators for the, Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes10.1007/s00125-004-1640-z ↗
60. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide10.1007/s11154-012-9235-3 ↗
61. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms10.1161/CIRCULATIONAHA.105.563213 ↗
62. The endothelial cell: an “early responder” in the development of insulin resistance10.1007/s11154-012-9232-6 ↗
63. Endoplasmic reticulum stress in insulin resistance and diabetes10.1016/j.ceca.2014.08.006 ↗
64. Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature10.3389/fendo.2013.00068 ↗
65. Influence of clinically relevant mechanical forces on vascular smooth muscle cells under chronic high glucose: an in vitro dynamic disease model10.1016/j.avsg.2016.04.003 ↗
66. Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease10.1093/ndt/gfg200 ↗
67. Vascular calcification: pathophysiology and risk factors10.1007/s11906-012-0265-8 ↗
68. Biology of calcification in vascular cells: intima versus media10.1007/PL00002027 ↗
69. Vascular calcification in diabetes: mechanisms and implications10.1007/s11892-013-0379-7 ↗
70. Vascular calcification, diabetes, and cardiovascular disease: connecting the dots10.1016/j.jcmg.2012.02.006 ↗
71. RAGE biology, atherosclerosis and diabetes10.1042/CS20100501 ↗
72. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells10.5551/jat.7120 ↗
73. Ca(2+) handling alterations and vascular dysfunction in diabetes10.1016/j.ceca.2014.08.007 ↗
74. Vascular calcification: from pathophysiology to biomarkers10.1016/j.cca.2014.08.034 ↗
75. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice10.1016/j.ajpath.2015.03.020 ↗
76. Ca2+-sensing receptor cleavage by calpain partially accounts for altered vascular reactivity in mice fed a high-fat diet10.1097/FJC.0b013e31828d0fa3 ↗
77. Association studies of calcium-sensing receptor (CaSR) polymorphisms with serum concentrations of glucose and phosphate, and vascular calcification in renal transplant recipients10.1371/journal.pone.0119459 ↗
78. A role for the endothelium in vascular calcification10.1161/CIRCRESAHA.113.301792 ↗
79. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress10.1186/1471-2261-13-13 ↗
80. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways10.1016/j.atherosclerosis.2009.06.007 ↗
81. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bellwether for vascular disease?10.1016/j.cardiores.2007.06.016 ↗
82. Potential role of the adventitia in arteritis and atherosclerosis10.1016/S0167-5273(96)02811-2 ↗
83. Dupuytren's contracture: fibroblast contraction?An ultrastructural study
84. The story of the myofibroblasts10.1097/00000478-197912000-00006 ↗
85. Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice10.1016/j.atherosclerosis.2013.01.018 ↗
86. A cardiac patch from aligned microvessel and cardiomyocyte patches
87. Contribution of pericyte paracrine regulation of the endothelium to angiogenesis10.1016/j.pharmthera.2016.10.001 ↗
88. Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes10.1016/S0091-679X(08)00013-7 ↗
89. Pericytes, an overlooked player in vascular pathobiology10.1016/j.pharmthera.2016.11.008 ↗
90. Activation of the pro-oxidant PKCbetaII-p66Shc signaling pathway contributes to pericyte dysfunction in skeletal muscles of patients with diabetes with critical limb ischemia10.2337/db16-0248 ↗
91. Small-diameter artificial arteries engineered in vitro10.1161/01.RES.0000196867.12470.84 ↗
92. Review: application of stem cells for vascular tissue engineering10.1089/ten.2005.11.1535 ↗
93. Vascular tissue engineering: from in vitro to in situ10.1002/wsbm.1246 ↗
94. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells, American journal of physiology10.1152/ajpheart.01232.2003 ↗
95. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells10.1002/stem.319 ↗
96. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model
97. Availability of adipose-derived stem cells in patients undergoing vascular surgical procedures10.1016/j.jss.2010.04.025 ↗
98. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential10.1080/14653240310003026 ↗
99. Adipose-derived stem cells for regenerative medicine10.1161/01.RES.0000265074.83288.09 ↗
100. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells10.1089/scd.2011.0031 ↗